Kane J M
Department of Psychiatry, Albert Einstein College of Medicine, Long Island Jewish Medical Center, Hillside Hospital, Glen Oaks, NY 11004, USA.
Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S3-6. doi: 10.1097/00004850-199705002-00002.
Although considerable progress has been made in the management of schizophrenia, much remains to be achieved in meeting the therapeutic needs of patients with this illness. Conventional antipsychotics have revolutionized treatment, but a substantial proportion of patients derive inadequate benefit and many suffer from adverse effects. Compliance with medication remains an enormous problem. With a number of new drugs soon to be available, it is hoped that valuable alternatives can be provided, increasing the possibility of good therapeutic response and increasing the benefit-to-risk ratio.
尽管在精神分裂症的治疗方面已经取得了相当大的进展，但在满足这种疾病患者的治疗需求方面仍有许多工作要做。传统抗精神病药物彻底改变了治疗方式，但相当一部分患者受益不足，许多人还遭受不良反应。药物依从性仍然是一个巨大的问题。随着一些新药即将问世，人们希望能够提供有价值的替代药物，增加获得良好治疗反应的可能性，并提高效益风险比。
